Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
-$0.16 today
- Market cap
- $72.48M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
Volume 0.15M
Average 0.16M
COYA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Coya Therapeutics, Inc.NASDAQ: COYA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $2.81K fell 59.0% year over year, behind the -14.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 59.0% from the prior quarter. Over 3 fiscal years it compounded at +0.0% a year.
Context
- Depreciation & amortization amounted to 0.3% of revenue in FY2025, down 0.4 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -59.0% toward the trailing-twelve-month pace of -14.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 27.36K USD
- Year-over-year change
- +0.0%
- 4-year CAGR
- +14.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.36K | +0.0% |
| FY2024 | 2024-12-31 | 27.36K | +0.0% |
| FY2023 | 2023-12-31 | 27.36K | +0.0% |
| FY2022 | 2022-12-31 | 27.36K | +69.6% |
| FY2021 | 2021-12-31 | 16.13K | — |
Depreciation & Amortization vs competitors
How COYA compares with its peers on the latest reported figures
- COYA's LTM Mar 2026 depreciation & amortization of $23.33K is the 10th largest of the 11 companies compared; the peer median is $532.04K.
- Its year-over-year change of -14.7% is the 6th highest of 11, against a peer median of -18.9%.
- Depreciation & amortization amounts to 0.3% of revenue for COYA, versus a peer median of 4.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.94M | -7.1% | -22.5% | 4.4% | |
| LTM Mar 2026 | $3.64M | -3.9% | +6.3% | 364.3% | |
| LTM Mar 2026 | $1.51M | -26.6% | -2.4% | — | |
| LTM Mar 2026 | $1.45M | -11.2% | +13.6% | 1079.1% | |
| LTM Mar 2026 | $628K | -48.8% | -19.7% | — | |
| LTM Mar 2026 | $436.09K | +189.3% | +454.8% | — | |
| LTM Mar 2026 | $168K | -72.2% | -41.8% | 2.4% | |
| LTM Mar 2026 | $121K | -27.5% | +27.8% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $79K | -59.1% | -20.8% | 1.1% |
| LTM Mar 2026 | $23.33K | -14.7% | +0.0% | 0.3% | |
| LTM Mar 2026 | $16.88K | +36.5% | +20.6% | — | |
| Peer median (excluding COYA) | $532.04K | -18.9% | +1.9% | 4.4% | |
Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.89M) | (12.24M) | (7.99M) | (14.88M) | (21.23M) |
| Depreciation & Amortization | 16.13K | 27.36K | 27.36K | 27.36K | 27.36K |
| Deferred Income Tax | 399.68K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 233.22K | 207.35K | 872.25K | 2.66M | 4.29M |
| Change in Working Capital | 739.17K | 751.84K | (4.64M) | 1.88M | 3.88M |
| Accounts Receivables | 0 | 0 | (7.5M) | 7.5M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 665.17K | 845.28K | 298.82K | 477.45K | (527.01K) |
| Other Working Capital | 74K | (93.45K) | 2.56M | (6.1M) | 4.41M |
| Other Non-Cash Items | (399.68K) | 4.02M | 543.19K | 25K | 2.29M |
| Operating Cash Flow | (3.9M) | (7.24M) | (11.19M) | (10.29M) | (10.74M) |
| Capital Expenditures | (136.8K) | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (525K) | (543.19K) | (25K) | 0 |
| Investing Cash Flow | (136.8K) | (525K) | (543.19K) | (25K) | (1.16M) |
| Debt Repayment | 0 | 10.47M | 0 | 0 | 0 |
| Common Stock Issued | 1.32K | 158 | 38.34M | 14M | 20.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (341.9K) | (1.11M) | 89.95K | 2.02M | 0 |
| Financing Cash Flow | (340.58K) | 9.36M | 38.43M | 16.03M | 20.39M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.38M) | 1.59M | 26.69M | 5.71M | 8.48M |
| Free Cash Flow | (4.04M) | (7.24M) | (11.19M) | (10.29M) | (10.74M) |
Coya Therapeutics, Inc.
NASDAQ:COYA
Intrinsic Alpha fair value
Locked
Current Price
$3.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.